Employer healthcare costs are surging to historic levels, driven largely by prescription drug costs. According to the PwC Medical Cost Trend 2027 report, the projected commercial group medical cost trend has reached 9.0%, which is the highest it has been in 17 years.
For self-funded insurance plan sponsors, this rapid growth makes budget planning far more unpredictable. Unlike fully insured plans, self-funded employers directly absorb the cost of pharmacy claims. Managing them requires more than traditional tactics, such as basic formulary updates, general prior authorizations, or higher deductibles.
To bend the cost curve, organizations running self-funded health insurance plans must look beyond standard cost-containment. A comprehensive approach that incorporates data analytics, formulary optimization, and clinical oversight can make the difference between a sustainable benefits program that maintains and one that requires painful trade-offs year after year.
The seven strategies in this article provide a practical framework for self-funded employers to proactively manage expenditures while maintaining patient care quality and employee satisfaction.
Why Pharmacy Costs Are Rising for Self-Funded Employers
Several converging factors are driving pharmacy spend upward, and most of them aren’t going away. These include:
Specialty Medications
High-cost treatments now account for about 55% of total pharmacy spending, driven by just 2% of a plan’s members, according to a 2026 market report from RxBenefits.
Of note, GLP-1 prescriptions for weight loss have added costs that most benefit designs weren’t designed to absorb. In 2025, more than 60% of large employers reported that GLP-1s moderately or significantly increased their pharmacy spending.
Drug Price Inflation
The upward trend continues across standard and branded medications. However, many employers simply lack the visibility into their own pharmacy data to identify where spend is concentrated until it becomes a budget problem too significant to be absorbed or ignored.
Proven Pharmacy Cost Reduction Strategies for Self-Funded Employers
The following seven strategies give self-funded employers a framework for building a more sustainable pharmacy benefits program. Used strategically, they enable organizations to manage expenditures proactively rather than reacting to cost increases after they occur.
1. Use Pharmacy Spend Analytics to Identify Savings Opportunities
Before cost reduction strategies can work, employers need a clear picture of where pharmacy dollars are going. Analytics platforms that identify and track data such as utilization trends, medication cost increases, and prescribing patterns by member population provide benefits teams with the information they need to act.
Data allows employers to prioritize the interventions most likely to produce meaningful savings for their specific plan. Without it, cost containment efforts are mostly guesswork.
2. Implement Automated Pharmacy Cost Containment Solutions
Manual pharmacy audits are still essential, but they can’t be used on their own to effectively manage spending. For one, they review spending that has already occurred, when the only thing employers can do is chase after overpayments.
Compounding matters, manual audits typically look at a tiny fraction of total annual claims. In an era of multi-million dollar cell and gene therapies and skyrocketing GLP-1 utilization, a retrospective sample size that small creates a massive blind spot for employers, health plans, and TPAs.
In contrast, an automated cost-containment platform monitors claims and flags savings opportunities as they surface. This allows plan sponsors to identify lower-cost therapeutic alternatives, biosimilar options, and potential dosing optimizations sooner.
RazorMetrics’ RxEdge helps self-funded employers address these vulnerabilities with a proactive approach. Instead of traditional tactics, such as shifting the burden of cost comparison to the employee, RxEdge targets the primary decision-maker: the prescriber.
By embedding formulary data and lower-cost therapeutic alternatives directly into the workflows that physicians utilize daily, the platform intercepts high-cost prescriptions sooner. This allows plan sponsors to prevent unnecessary expenditures at the source, ensuring plan sustainability while maintaining uninterrupted care for members.
3. Focus on Specialty Drug Cost Containment
Specialty medications comprise a significant portion of pharmacy spend. Biologics and branded specialty drugs carry significant price tags, and without active monitoring, plans continue paying for them even when less costly biosimilar alternatives have become available.
Effective specialty drug management means maintaining current formulary data, tracking biosimilar approvals, and matching substitution opportunities to prior authorization requirements as they arise. Automated platforms can continuously monitor these changes and match patients with biosimilar alternatives, eliminating longer lag time associated with manual reviews.
By automating the management of specialty drug pipelines, plan sponsors can deploy highly targeted cost containment approaches, such as:
- Biosimilar Substitution Alerts: Automatically flagging when a biosimilar becomes available for a specialty prescription and routing the switch recommendation to the prescriber
- Prior Authorization Optimization: Updating PA requirements as biosimilars enter the market, ensuring patients can access lower-cost alternatives without delay
- Specialty Formulary Updates: Maintaining current tier placements and reimbursement rates as new biosimilars launch, preventing plans from overpaying for legacy products
- Provider Education Prompts: Delivering biosimilar availability and cost-comparison data directly to prescribers, closing the information gap that keeps patients on expensive originals
4. Optimize Pharmacy Benefits and Formulary Management
A formulary that hasn’t been reviewed recently is likely generating unnecessary spend. Aligning formulary design with both clinical outcomes and cost data ensures the medications available to members reflect current pricing and therapeutic evidence.
Formulary optimization also means creating incentives for cost-effective choices at the prescribing level, not just at the pharmacy counter. When lower-cost alternatives are built into the benefit design, members and physicians are more likely to choose them by default.
5. Increase Transparency Into Prescription Drug Spending
RazorMetrics’ 2026 State of Drug Access Survey found that over 75% of insured consumers experience cost distress below $250. Because sticker shock hits at routine price points rather than just high-cost specialty drugs, patients frequently delay filling prescriptions or skip doses entirely, ultimately driving up downstream healthcare costs.
Improving transparency requires giving plan administrators and members better visibility into medication costs alongside clear data on where the plan’s dollars are going. When employers can easily see if cheaper alternatives exist, they can take action. Regular reporting on spend by drug category, prescriber, and member population makes it easier to spot these cost drivers.
6. Encourage the Use of Lower-Cost Therapeutic Alternatives
Generic adoption, biosimilar substitution, and therapeutic switching are among the highest-return cost containment strategies available to self-funded employers. Perhaps surprisingly, what’s stopping consumers isn’t a lack of willingness to switch: RazorMetrics’ survey found that 80-85% of consumers trust generic drugs, and 83.9% say they want their provider to switch them to the lowest-cost option automatically.
The barriers stem from not knowing that a less expensive, clinically identical alternative is even an option, and from the difficulty of explaining their needs to their doctors and securing a new prescription.
The disconnect between consumer preference and actual prescribing behavior can be attributed to a workflow issue. Physicians often lack complete visibility into a patient’s full medication profile, available biosimilars, and formulary options at the point of prescribing. Solutions that deliver this information directly to prescribers close that gap without requiring members to navigate the process themselves.
7. Regularly Review Pharmacy Cost Containment Performance
Cost containment programs lose effectiveness when they aren’t monitored. Tracking savings generated, measuring ROI, and regularly reviewing acceptance rates and switch outcomes allow employers to identify what’s working and adjust what isn’t.
Performance data also builds the internal case for continued investment. When benefits teams can show concrete savings figures alongside member satisfaction data, it becomes easier to maintain and expand cost management programs rather than scale them back under budget pressure.
How Self-Funded Employers Can Build a Long-Term Pharmacy Cost Management Strategy
No single tactic solves rising pharmacy costs. The employers seeing the most durable results are combining analytics, automation, and clinical oversight into an ongoing program rather than a one-time intervention.
That means starting with data to understand the plan’s specific cost drivers, layering in automation to capture savings continuously, and using performance reporting to refine the approach over time.
Cost containment strategies built on these three elements don’t just reduce spend in year one. They create a structure that keeps working as the plan grows, formularies change, and new medications enter the market.
For employers running self-funded health insurance, building this infrastructure is one of the highest-return investments available in benefits management. The alternative is absorbing cost increases reactively, year after year, with limited tools to change the trajectory.
How RazorMetrics Helps Employers Reduce Pharmacy Spend
RazorMetrics provides pharmacy cost containment solutions for self-funded employers, payors, PBMs, unions, and state government programs. A physician-directed approach routes savings recommendations into existing clinical workflows, resulting in acceptance rates far higher than those for member-facing outreach. Clients reduce drug spend by up to 10%, with 100% saving within 120 days of deployment.
RazorMetrics also works with benefits consultants, TPAs, and other partners looking to add pharmacy cost containment to their service offering.
Two core solutions work together to reduce prescription drug costs with minimal lift for plan sponsors:
RxEdge continuously identifies savings opportunities in biosimilar substitution and polypharmacy management, routing recommendations directly to prescribers with no integration required.
RxAdvocate gives employees easy savings and notifications through a simple web portal.
Start Reducing Pharmacy Spend Before Next Renewal
Understanding how to reduce healthcare costs for employees starts with having the right tools in place to monitor, identify, and act on savings opportunities sooner. A combination of analytics, automation, and physician-directed outreach gives self-funded plans the ability to meaningfully reduce pharmacy spend rather than absorb it.
To see how RazorMetrics can reduce pharmacy costs for your plan, schedule a demo today.
